Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
|
Total sales from the HIV franchise were $19.6
billion in 2024, up 8% year over year, driven by strong growth in lead HIV
treatment Biktarvy. GILD ... |
Nearly 3 million extra deaths by 2030 could result from HIV funding cuts, study suggests
"The widespread rollout and uptake of antiretroviral therapy funded by international sources has been one of the most important factors reducing ... View article...